HQL

HoldBargain Bin

Abrdn Life Sciences Investors · Financial Services · United States · $585M cap · $2.2M/day traded

$17.26 -4.1% · close 13 Oct · scored 14 Oct

StockRank down 4.7 since 13 Oct: Momentum down 5 after a 4% price fall.

Bargain Bin: Looks like a bargain; the quality and the trend say why it is in the bin.

43
StockRank
Get score and insider alerts
Quality
34
Value
58
Momentum
43

As of 14 Oct 2026, MoatMap's StockRank for Abrdn Life Sciences Investors (HQL) is 43/100, ranked against 24,000+ stocks in 35 markets (Quality 34, Value 58, Momentum 43, each scored against its sector).

Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →

P/E (TTM)
2.6x
peers 12.4x
ROE
41.4%
peers 9.7%
D/E
0.0x
peers 0.3x
Dividend %
12.3%
trailing yield

ABOUT ABRDN LIFE SCIENCES INVESTORS

Read

abrdn Life Sciences Investors is a closed-end fund that invests in public and private companies within the life sciences industry, including biotechnology, pharmaceuticals, and medical devices. The fund's competitive advantage lies in its ability to invest a portion of its assets in venture-stage, privately held companies, offering retail investors rare access to early-stage healthcare innovations. It is managed by abrdn's specialized healthcare team, targeting long-term capital appreciation through a diversified portfolio of cutting-edge science companies.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGRTTM
Revenue—-103.3M23.5M86.7M86.4M91.6%—
EPS2.66-4.260.793.042.791.2%6.91
Shares—25.7M26.8M28.1M29.6M+15.3%—
Debt———————
Equity—397.9M401.9M459.7M513.7M8.9%—
Op CF————31.7M—39.8M
Inv CF———————
Fin CF————-31.6M——
Loading 1Y...
PRICE (1Y) · USD-17.3%
17.318.219.120.021.01 Sep23 Sep13 Oct
SMA 50SMA 200

Price checkNo clear trendExperimental

No clear trend: not near its 52-week low, and not in a steady uptrend.

SwingsCalm

Calmer than 85% of stocks we rank over the past year (24% a year).

How this is worked out

StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$17.26
RSI (14)
22.4
52-Week Range-21.7% from high
Low $13.85High $22.04

SCORE BREAKDOWN

Quality
34
ROIC (ROA)
-0.6%*10.6
ROE
41.4%96.4
GP/Assets
0.2%3.6
Op. Margin
-516.5%1.0
FCF/Assets
-0.8%20.4
Piotroski
213.2
Int. Cover
—N/A
D/E Ratio
0.00x95.0
Current Ratio
1.61x50.6
Value
58
P/E (TTM)
2.6x98.4
EV/EBITDA
n/mN/A
P/FCF
n/mN/A
P/B
1.0x58.8
P/S
—N/A
Div Yield
12.3%93.2
Momentum
43
52W High %
78%28.9
RS 6M
-9%44.6
SMA 50/200
1.14x86.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$585M
P/E (Forward)
—
Gross Margin
100.0%

SECTOR PEERS

Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of HQL are excluded.

TickerCompanyMkt CapStockRankSignal
HQLAbrdn Life Sciences Investors(you)$585M43Hold
NMLNeuberger Berman Income Funds - Neuberger Energy Infrastructure and Income Fund Inc.$589M41Hold
PFNPIMCO Income Strategy Fund II$619M42Hold
VKQInvesco Municipal Trust$536M41Hold
SLRCSLR Investment Corp.$642M41Hold
IQIInvesco Quality Municipal Income Trust$526M44Hold
PMLPIMCO Municipal Income Fund II$485M43Hold
VMOInvesco Municipal Opportunity Trust$647M46Hold
GUTThe Gabelli Utility Trust$541M40Hold
MFICMidCap Financial Investment Corporation$733M43Hold

Peer medians: ROE 9.7% · P/E 12.4x · Gross margin 100.0%

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

Abrdn Life Sciences Investors (HQL): Stock Score Summary

Abrdn Life Sciences Investors (HQL) has a MoatMap StockRank of 43/100 based on Quality (34/100), Value (58/100), and Momentum (43/100) factor scores. The current signal is HOLD.

abrdn Life Sciences Investors is a closed-end fund that invests in public and private companies within the life sciences industry, including biotechnology, pharmaceuticals, and medical devices. The fund's competitive advantage lies in its ability to invest a portion of its assets in venture-stage, privately held companies, offering retail investors rare access to early-stage healthcare innovations. It is managed by abrdn's specialized healthcare team, targeting long-term capital appreciation through a diversified portfolio of cutting-edge science companies.

Key Financial Metrics

Price$17.26
Market Cap$585M
P/E (TTM)2.63
Price/Book0.98
Return on Equity41.4%
Debt/Equity0.00x
Gross Margin100.0%
Operating Margin-516.5%
Revenue Growth-60.8%
Dividend Yield12.3%
Free Cash Flow$-4M

Abrdn Life Sciences Investors operates in the Asset Management industry, part of the Financial Services sector (United States).

Frequently Asked Questions

What is Abrdn Life Sciences Investors’s (HQL) StockRank?
MoatMap’s StockRank for Abrdn Life Sciences Investors (HQL) is 43/100, with a Hold signal. It is a composite of Quality (34), Value (58), and Momentum (43), each scored against its sector. The composite is then ranked across MoatMap’s universe of 24,000+ stocks.
Does Abrdn Life Sciences Investors have an economic moat?
Abrdn Life Sciences Investors (HQL) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Abrdn Life Sciences Investors a buy, hold, or sell?
MoatMap’s current signal for Abrdn Life Sciences Investors (HQL) is Hold, based on a StockRank of 43/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Abrdn Life Sciences Investors in?
Abrdn Life Sciences Investors (HQL) operates in the Financial Services sector, specifically the Asset Management industry (United States).